Latest Financials News

Alfabs Australia Limited reported robust financial gains in FY2025, including a maiden dividend and major contract completion, while signaling cautious optimism for 2026 amid softer markets and uncertain project pipelines.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chrysos Corporation reported record FY25 financial results, driven by strong global demand for its innovative PhotonAssay™ technology. The company expanded its footprint, enhanced sustainability credentials, and strengthened governance, positioning itself for continued growth.

Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.

SPC Global Holdings delivered a transformational FY25 with robust financial results and strategic international growth, setting the stage for a confident 25% EBITDA increase in FY26.

Rox Resources (ASX – RXL) has delivered a comprehensive update on its Youanmi Gold Project, highlighting a compelling Definitive Feasibility Study and significant funding progress that set the stage for production in 2026.

Comms Group has secured a new $10.7 million refinancing package with improved terms, including additional funding capacity for acquisitions and equipment finance. This move aims to enhance financial flexibility and support future growth initiatives.

Skylark Minerals has acquired a high-grade gold portfolio in Côte d'Ivoire, including a flagship project with a 364,600-ounce inferred resource, marking a significant step in its West African growth strategy. The company is fully funded to accelerate exploration in early 2026, targeting resource expansion and new discoveries.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Metro Performance Glass Limited has returned to profitability in the first half of 2025, posting a NZD 4.5 million profit before tax and significantly reducing its debt through a NZD 23.9 million equity raise.

Metroglass has reported a 5% revenue decline in its half-year results but achieved a significant reduction in net debt and improved profitability, signaling progress in its turnaround strategy amid challenging market conditions.